CervoMed Inc. - Asset Resilience Ratio
CervoMed Inc. (CRVO) has an Asset Resilience Ratio of 9.52% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CervoMed Inc. working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how CervoMed Inc.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is CervoMed Inc.'s balance sheet.
Liquid Assets Composition Over Time
This chart breaks down CervoMed Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore CRVO long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.48 Million | 9.52% |
| Total Liquid Assets | $2.48 Million | 9.52% |
Asset Resilience Insights
- Limited Liquidity: CervoMed Inc. maintains only 9.52% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
CervoMed Inc. Industry Peers by Asset Resilience Ratio
Compare CervoMed Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for CervoMed Inc. (2021–2025)
The table below shows the annual Asset Resilience Ratio data for CervoMed Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 53.97% | $12.63 Million | $23.40 Million | -15.48pp |
| 2024-12-31 | 69.46% | $29.92 Million | $43.08 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $9.97 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $37.84 Million | -- |
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood"brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and sl… Read more